Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Ophthalmology. 2012 Jul 13;119(11):2377–2385. doi: 10.1016/j.ophtha.2012.05.032

Table 5. Cox Regression Model of Hazard Ratio for IOP<5mmHg, sustained for at least 30 days.

Univariate
n=6,785
events=126
Multivariate
n=6,540
event=97
Events/
At Risk
Hazard Ratio
(95% Confidence
Interval)
p-
value
Events/
At Risk
Hazard Ratio
(95% Confidence
Interval)
p-
value
Age <18 45/973 4.97 (2.58 - 9.57) <.001 36/933 2.92 (1.20 - 7.10) 0.15
18-25 22/897 2.50 (1.21 - 5.15) 19/878 2.27 (0.98 - 5.27)
26-35 15/1483 Reference 12/1458 Reference
36-45 15/1300 1.19 (0.53 - 2.65) 11/1275 0.99 (0.40 - 2.43)
46-55 13/983 1.39 (0.63 - 3.08) 9/963 1.00 (0.35 - 2.85)
56-65 6/556 1.14 (0.39 - 3.35) 5/548 0.79 (0.22 - 2.82)
>65 7/497 1.87 (0.69 - 5.07) 5/485 0.84 (0.24 - 2.97)
Race White 73/4755 Reference 0.002 55/4629 Reference 0.74
African-derived 42/1208 2.22 (1.42 - 3.46) 32/1148 1.25 (0.71 - 2.22)
Other 11/822 1.10 (0.52 - 2.30) 10/763 1.03 (0.49 - 2.14)
Contralateral uveitis No 8/1170 Reference 0.02 8/1144 Reference 0.41
Yes 118/5615 2.35 (1.14 - 4.87) 89/5396 1.39 (0.63 - 3.07)
Hypertension No 86/5547 Reference 0.006 70/5351 Reference 0.052
Yes 40/1238 1.89 (1.20 - 2.97) 27/1189 2.04 (0.99 - 4.20)
Systemic Diseases Behçet’s disease, HLA-B27,
spondyloarthropathy,
and/or Sarcoidosis
57/1846 1.80 (1.20 - 2.72) 0.005 43/1775 0.79 (0.42 - 1.49) 0.46
Juvenile idiopathic
arthritis
33/329 6.13 (3.83 - 9.81) <.001 25/297 2.04 (0.79 - 5.31) 0.14
Type of Uveitis Anterior Uveitis 74/3609 Reference <.001 61/3459 Reference <.001
Intermediate Uveitis 6/1197 0.20 (0.07 - 0.58) 4/1169 0.17 (0.05 - 0.56)
Posterior Uveitis 3/1112 0.10 (0.03 - 0.31) 2/1087 0.11 (0.03 - 0.45)
Panuveitis 43/867 1.93 (1.24 - 3.01) 30/825 1.25 (0.67 - 2.35)
Duration of uveitis at
presentation
<6 months 18/2749 Reference <.001 10/2613 Reference 0.002
6 months to 2 years 15/1401 1.46 (0.67 - 3.17) 14/1382 1.52 (0.59 - 3.94)
2 to 5 years 27/1134 3.36 (1.68 - 6.69) 26/1112 4.53 (1.94 - 10.61)
Greater than 5 years 66/1501 6.13 (3.33 - 11.26) 47/1433 3.08 (1.30 - 7.31)
Prior Cataract Surgery by
Type
None 32/* Reference <.001 19/* Reference <.001
Phacoemulsification 13/* 4.21 (2.15 - 8.27) 13/* 4.87 (2.25 - 10.55)
Extracapsular cataract
extraction (ECCE)
17/* 8.00 (4.34 - 14.73) 16/* 6.50 (3.14 - 13.45)
Intracapsular cataract
extraction (ICCE)
11/* 22.20 (9.32 - 52.89) 8/* 12.19 (3.78 - 39.30)
Pars plana lensectomy 19/* 25.63 (13.86 -
47.40)
18/* 8.51 (3.12 - 23.21)
Unknown 34/* 13.98 (8.10 - 24.13) 23/* 7.28 (3.31 - 16.00)
Prior Pars Plana
Vitrectomy
No 89/* Reference <.001 63/* Reference 0.008
Yes 37/* 5.58 (3.61 - 8.62) 34/* 2.03 (1.21 - 3.42)
Prior Retinal Detachment
Surgery
No 118/* Reference <.001 91/* Reference 0.88
Yes 8/* 4.87 (2.24 - 10.59) 6/* 0.92 (0.29 - 2.89)
Anterior chamber cells Quiet 72/* Reference 0.03 58/* Reference 0.45
0.5+ 26/* 1.94 (1.20 - 3.14) 19/* 0.86 (0.46 - 1.58)
1+ 14/* 1.76 (0.93 - 3.35) 13/* 1.24 (0.63 - 2.46)
2+ 4/* 0.78 (0.28 - 2.14) 3/* 0.31 (0.08 - 1.14)
3+ or worse 5/* 1.87 (0.76 - 4.63) 4/* 0.97 (0.32 - 2.94)
Structural complications Exudative detachment 9/* 14.15 (6.77 - 29.55) <.001 9/* 5.25 (1.86 - 14.80) 0.002
*

The number at risk for time-varying characteristics changes over followup, and is therefore not reported as a number of patients